Exane Derivatives’s DexCom DXCM Stock Holding History

Exane Derivatives’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,196	Closed	-$153K	–	837
2022 Q1	$153K	Sell	1,196 -304	-20%	-$33.3K	0.04%	395
2021 Q4	$201K	Sell	1,500 -444	-23%	-$63.8K	0.05%	328
2021 Q3	$266K	Sell	1,944 -1,736	-47%	-$219K	0.06%	319
2021 Q2	$411K	Buy	3,680 +720	+24%	+$69.1K	0.09%	230
2021 Q1	$266K	Sell	2,960 -1,276	-30%	-$120K	0.08%	247
2020 Q4	$392K	Buy	+4,236	New	+$378K	0.12%	206

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exane Derivatives's DXCM Position: Q2 2022 in Review

Exane Derivatives sold out of DexCom (DXCM) in Q2 2022, closing a stake of 1,196 shares — an estimated $153K sold.

Exane Derivatives first reported a position in DXCM in Q4 2020 and held it in 6 quarters. The position peaked at $411K in Q2 2021. 798 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Exane Derivatives reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 1,196 DexCom shares in Q2 2022, an estimated $153K.
Exane Derivatives first reported a position in DexCom in Q4 2020 and held it in 6 quarters.
Exane Derivatives's DexCom position peaked at $411K in Q2 2021.
798 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.